



**The 65th Annual Meeting of the Pacific Coast Reproductive Society**  
**MARCH 22 - 26, 2017 • Renaissance Hotel, Indian Wells, California**

**Title:**

***A ROBUST PROGESTERONE ( $P_4$ ) RISE POST-SURGE IS INDICATIVE OF ADEQUATE LUTEINIZATION AND CONFERS IMPROVED PREGNANCY OUTCOMES EVEN IN THE PRESENCE OF A POST-TRIGGER FALL IN ESTRADIOL ( $E_2$ )***

**Authors:**

T.G. Nazem, 1,2 J. Rodriguez-Purata,1 L. Sekhon,1,2 C. Hernandez-Nieto,1 J. A. Lee,1 A. B. Copperman,3,2 B. Sandler1,2

**Affiliations:**

1. Reproductive Medicine Associates of New York, 635 Madison Ave 10th Floor New York, New York, United States, 10022
2. Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, Klingenstein Pavilion 1176 Fifth Avenue 9th Floor New York, New York, United States, 10029.

**Background:**

After ovulation, primary production of estradiol ( $E_2$ ) by granulosa cells cease and secondary secretion of progesterone ( $P_4$ ), a LH-mediated activity, begins. A decrease in  $E_2$  at post-ovulation trigger (Day +1) can signify poor oocyte quality after retrieval and may prompt cancellation of the cycle.

**Objective:**

The study evaluated the effect of an unpredictable drop in serum  $E_2$  after surge on pregnancy outcomes. A secondary aim of the study was to assess whether degree of luteinization, particularly a high post-ovulation trigger  $P_4$ , impacted outcomes in the setting of a decrease in  $E_2$ .

**Materials and Methods:**

This retrospective study includes patients undergoing IVF between 2005-2015 who had a decrease in  $E_2$  on Day+1 and had a measured  $P_4$  at surge. Patients were segregated according to percentage  $E_2$  decrease on Day+1: A)  $\leq 10\%$ ; B)  $>10\% \leq 25\%$ ; C)  $>25\% \leq 40\%$ ; D)  $>40$ . Using these cohorts, secondary analysis included degree of luteinization, and patients were segregated accordingly ( $\leq 3\text{ng/mL}$ ;  $>3\text{ng/mL}$ ). Main outcome measures were pregnancy rate (PR), clinical PR, early pregnancy loss rate and live birth rate (LBR). Bivariate associations were examined using Pearson's Chi-square test and independent samples t-test, as appropriate. All statistical tests were two-sided and p-value $<0.05$  was considered statistically significant.



**Result(s):**

Of cycles analyzed, 1432 met the study’s inclusion criteria [Table 1]. Age, day 3 FSH, basal AFC and endometrial thickness were similar between groups. Peak E<sub>2</sub> level at surge, E<sub>2</sub> level at Day+1, oocytes retrieved, number of embryos ongoing on day 1 and the number of embryos transferred were also similar between groups except for Group E, as there were no oocytes retrieved. PR, clinical PR and LBR decreased, while miscarriage rates increased with incremental drop of E<sub>2</sub>. When P<sub>4</sub> on Day+1 was >3 ng/mL, higher PR, clinical PR and LBR were observed regardless of decrease in E<sub>2</sub>.

**Conclusion(s):**

As previously reported, an E<sub>2</sub> decrease on Day+1 is associated with lower pregnancy rates in fresh IVF cycles. Adequate or robust luteinization, as evident by a post-surge two-fold or greater P<sub>4</sub> increase, was associated with higher PR and clinical PR in each cohort. The rise in P<sub>4</sub> may serve as a surrogate marker for documenting the adequacy of ovarian response to trigger and controlled ovarian stimulation. This data provides clinicians with a deeper understanding of the dynamics of successful luteinization, enabling them to better counsel patients and to maximize cycle success.

**Table 1: Cycle Parameters and Outcomes based on Percentage Decrease in E<sub>2</sub>**

	<10% (n=1240)	<25% (n=526)	<40% (n=66)	>40% (n=9)
Age (years)	37.3±4.5	37.6±4.5	37.2±5.1	37.3±6.4
Peak E <sub>2</sub> (pg/mL)	2059.7±1090.7	2092.0±1192.0	2156.2±1177.9	2133.8±1246.7
PR (P <sub>4</sub> <3 ng/mL)	39.5% (227/575)	37.2% (86/231)	21.7% (5/23)	20.0% (1/5)
PR (P <sub>4</sub> ≥3 ng/mL)	50.8% (338/665)	46.4% (137/295)	51.2% (22/43)	50.0% (2/4)
Clinical PR (P <sub>4</sub> <3 ng/mL)	30.6% (176/575)	31.6% (73/231)	13.0% (3/23)	20.0% (1/5)
Clinical PR (P <sub>4</sub> ≥3 ng/mL)	41.4% (275/665)	35.6% (105/295)	39.5% (17/43)	25.0% (1/4)
Loss rate (P <sub>4</sub> <3 ng/mL)	15.7% (90/575)	14.7% (34/231)	17.4% (4/23)	0% (0/5)
Loss rate (P <sub>4</sub> ≥3 ng/mL)	17.3% (115/665)	19.0% (56/295)	18.6% (8/43)	25.0% (1/4)
LBR (P <sub>4</sub> <3 ng/mL)	22.9% (130/568)	21.8% (179/229)	4.3% (1/22)	25.0% (1/4)
LBR (P <sub>4</sub> ≥3 ng/mL)	32.9% (442/659)	26.0% (214/289)	30.2% (30/43)	25.0% (1/4)